Targeting CAFs to Improve Anti-PD-1 Checkpoint Immunotherapy

Daniele V.F. Tauriello*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The tumor microenvironment is a complex ecosystem that drives cancer progression and restrains immunity. Although immune checkpoint inhibitors have shown strong potential in a subset of patients, a better understanding of suppressive mechanisms may inspire ways to improve immunotherapeutic efficacy. A new study in this issue of Cancer Research focuses on targeting cancer-associated fibroblasts in preclinical models of gastric tumors. Aiming to rebalance anticancer immunity and enhance treatment responses to checkpoint-blocking antibodies, this work also addresses the potential for multitarget tyrosine kinase inhibitors in treating gastrointestinal cancer.

Original languageEnglish
Pages (from-to)655-656
Number of pages2
JournalCancer Research
Issue number5
Publication statusPublished - 2 Mar 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 American Association for Cancer Research.


Dive into the research topics of 'Targeting CAFs to Improve Anti-PD-1 Checkpoint Immunotherapy'. Together they form a unique fingerprint.

Cite this